MiNK Therapeutics (NASDAQ:INKT – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
MiNK Therapeutics Price Performance
INKT stock opened at $8.49 on Monday. The stock has a market capitalization of $33.65 million, a price-to-earnings ratio of -2.18 and a beta of 0.16. The business’s fifty day moving average price is $8.94 and its two-hundred day moving average price is $7.74. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $19.00.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their price objective on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th.
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- How to Build the Ultimate Everything ETF Portfolio
- What Are Earnings Reports?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is Short Interest? How to Use It
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.